Omega Therapeutics (OMGA)
$8.13
Insights on Omega Therapeutics
Decreasing Revenue
Revenue is down for the last 2 quarters, 734.0K → 516.0K (in $), with an average decrease of 29.7% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -30.82M → -24.05M (in $), with an average increase of 28.1% per quarter
Performance
- $8.00$8.88$8.13
1.6%
Downside
Day's Volatility :9.91%
Upside
8.45%
- $2.52$11.98$8.13
69.0%
Downside
52 Weeks Volatility :78.96%
Upside
32.14%
Returns
| Period | Omega Therapeutics | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 16.48% | 4.0% | -3.2% |
6 Months | 28.03% | -5.8% | -1.5% |
1 Year | 119.73% | 1.9% | -4.4% |
3 Years | -49.19% | 26.4% | 17.4% |
Highlights
Market Capitalization | 447.3M |
Book Value | $2.24 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -2.4 |
Wall Street Target Price | 11.71 |
Profit Margin | 0.0% |
Operating Margin TTM | -4680.1% |
Return On Assets TTM | -36.34% |
Return On Equity TTM | -70.85% |
Revenue TTM | 2.3M |
Revenue Per Share TTM | 0.05 |
Quarterly Revenue Growth YOY | 92.5% |
Gross Profit TTM | -74.0M |
EBITDA | -107.1M |
Diluted Eps TTM | -2.4 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.05 |
EPS Estimate Next Year | -2.04 |
EPS Estimate Current Quarter | -0.6 |
EPS Estimate Next Quarter | -0.62 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 44.03%
Technicals Summary
Sell
Neutral
Buy
Omega Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Omega Therapeutics | -3.44% | 28.03% | 119.73% | -49.19% | -49.19% |
 Moderna, Inc. | -6.6% | -29.55% | -6.79% | 114.56% | 571.72% |
 Regeneron Pharmaceuticals, Inc. | -0.63% | 0.01% | 30.35% | 23.26% | 140.46% |
 Novo Nordisk A/s | -5.39% | 23.69% | 41.34% | 146.71% | 255.68% |
 Seagen, Inc. | -2.64% | 57.03% | 37.37% | 30.74% | 191.76% |
 Vertex Pharmaceuticals Incorporated | -3.55% | 6.52% | 28.06% | 22.79% | 123.76% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Omega Therapeutics | NA | NA | NA | -2.05 | -0.71 | -0.36 | 0.0 | 2.24 |
Moderna, Inc. | 10.88 | 10.88 | 0.0 | -1.74 | 0.27 | 0.12 | 0.0 | 49.12 |
Regeneron Pharmaceuticals, Inc. | 20.15 | 20.15 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
Novo Nordisk A/s | 41.07 | 41.07 | 2.03 | 4.99 | 0.84 | 0.23 | 0.01 | 4.44 |
Seagen, Inc. | NA | NA | 18.53 | -2.89 | -0.23 | -0.12 | 0.0 | 14.54 |
Vertex Pharmaceuticals Incorporated | 25.51 | 25.51 | 0.41 | 14.57 | 0.26 | 0.17 | 0.0 | 56.05 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Omega Therapeutics | Buy | $447.3M | -49.19% | NA | 0.0% |
Moderna, Inc. | Buy | $47.9B | 571.72% | 10.88 | 31.77% |
Regeneron Pharmaceuticals, Inc. | Buy | $81.0B | 140.46% | 20.15 | 33.81% |
Novo Nordisk A/s | Buy | $356.5B | 255.68% | 41.07 | 32.47% |
Seagen, Inc. | Hold | $36.5B | 191.76% | NA | -31.55% |
Vertex Pharmaceuticals Incorporated | Buy | $85.1B | 123.76% | 25.51 | 35.4% |
Institutional Holdings
Flagship Ventures Management, Inc.
53.12%FMR Inc
8.36%Harbourvest Partners, LLC
6.38%Artal Group S A
4.60%State Of Wisconsin Investment Board
3.38%Vanguard Group Inc
2.54%
Corporate Announcements
Omega Therapeutics Earnings
Omega Therapeutics’s price-to-earnings ratio stands at None
Read More
Company Information
Organization | Omega Therapeutics |
Employees | 116 |
CEO | Dr. Noubar B. Afeyan Ph.D. |
Industry | Services |
Discover More
F45 Training Holdings Inc.
$0.80
+0.06%
Tilly's Inc
$6.73
+6.32%
Dennys
$11.73
-0.85%
Destination Xl Group Inc
$4.86
-1.42%
Bristow Group Inc
$24.30
-3.3%
Theseus Pharmaceuticals, Inc.
$9.28
-5.5%
Gigacloud Technology Inc
$7.00
+0.0%
Jianzhi Education Technology Group Company Ltd.
$1.02
+1.53%
Barrett Business Services Inc
$91.50
-0.11%